

# IC7: 0100 MRSA

### 1. Purpose

To outline the assessment, management, room placement and surveillance requirements of residents with Methicillin-Resistant Staphylococcus aureus (MRSA) to best meet the needs of the resident and prevent transmission within the facility.

## 2. Application of Standards

All residential healthcare facilities within the Fraser Health Authority.

## 3. Definitions

## Methicillin-Resistant Staphylococcus aureus (MRSA)

Strains of S. aureus resistant to oxacillin and cloxacillin. They may also be resistant to aminoglycosides, erythromycin, quinolones and other antibiotics.

### Healthcare-associated MRSA:

A case as defined above which is identified 3 calendar days (72 hours) after admission AND infection or colonization was not known to be present on admission OR MRSA is identified and patient was admitted to a healthcare facility within last 12 months

## **Community-associated MRSA:**

No previous history of MRSA infection or colonization within last 12 months AND diagnosis of MRSA made in outpatient setting or positive for MRSA within 3 days of hospital admission AND

no history (within past 12 months) of healthcare facility encounter, percutaneous device or indwelling catheter, dialysis or surgery

#### 4. Assessment

- 4.1. Routine admission screening for MRSA is **not done** in residential care.
- 4.2. Residents known to be positive for MRSA will be assessed regarding risk factors for transmission. These risk factors are:
  - 4.2.1. Draining wounds not contained by a dressing
  - 4.2.2. Colonized sputum with a productive cough
  - 4.2.3. Individuals with colonized tracheostomy and uncontrolled respiratory secretions

**Revised December 2013** 



- 4.2.4. Individuals with respiratory infections
- 4.2.5. Individuals with wound or stoma drainage that is not contained by a dressing or appliance
- 4.2.6. Individuals with desquamating skin conditions (e.g. psoriasis, burn patients)?
- 4.2.7. Individuals who are cognitively impaired
- 4.2.8. Individuals who have poor hygiene and are non-compliant with instructions
- 4.3 Residents will be admitted if colonization or infection with MRSA on admission.

#### 5. Management

- 5.1. Residents with an active MRSA infection with draining wounds that are not contained by a dressing are to be maintained on Contact precautions until the wound can be covered or the infection is resolved. See IC 6: 0400 Contact precautions and IC6:0410 Appendix I for Contact Precautions signage
- 5.2. Residents with colonized sputum and a productive cough are to be maintained on Droplet/Contact precautions for the duration of the productive cough. See IC6: 0600 Droplet/Contact precautions and IC6: 0600 Appendix I for Droplet /Contact precautions signage
- 5.3. For residents with colonized sputum and no cough they are to be maintained on routine practice
- 5.4. Residents that are colonized with MRSA are to be managed as per routine practice.
- 5.5. Resident hand hygiene is to be performed upon leaving their room.
- 5.6. Dedicate resident care equipment, slings, transfer belts, and ensure they low level disinfected (see IC13:0600) when removing from room.
- 5.7. Equipment that cannot be resident specific must be low level disinfected between uses. (IC13: 0600)
- 5.8. Bag soiled laundry at point of use
- 5.9. Dispose of waste through the general garbage.
- 5.10. Bathing frequency and routines are the same as other residents, follow established tub cleaning procedure.

**Revised December 2013** 

NOTE: This is a controlled document for Fraser Health (FH) internal use only. FH accepts no responsibility for use outside of this health authority. The electronic version of this document Clinical Policy Office is the current version – any printed versions should be checked against the electronic copy.



- 5.11. When transporting/transferring resident to another Facility for tests, procedures, or admission notify the receiving facility of MRSA status of the resident.
  - 5.11.1. Include the MRSA status on the written transfer documents.
  - 5.11.2. Notify transferring ambulance of MRSA status
- 5.12. For visiting/outings with family and friends encourage hand hygiene on entry and exit to room, unit and facility. When resident is on additional precautions all must follow instructions as per precautions card when in contact with the resident or the environment
- 5.13. **Do not** decolonization residents in residential care.

#### 6. Room Placement

- 6.1. A single room with dedicated bathroom is preferred.
- 6.2. Two or more residents with MRSA may share a room (cohort).
- 6.3. MRSA positive (colonized or infected) without risk factors may share a room with non-MRSA residents that do not have open wounds, ostomies or invasive devices including tubes, drains and catheters etc.
- 6.4. MRSA positive (colonized or infected) with risk factors may not share a room with non-MRSA residents that have open wounds, ostomies or invasive devices including tubes, drains and catheters etc.

#### 7. Outbreak

- 7.1. Ensure case definition for outbreak met, two or more person to person transmission of MRSA in a facility.
- 7.2. Increase cleaning to 2 X per day ensuring frequently touched surfaces are included in the second clean. Regular cleaning agent can be used. IPCP will request the enhanced cleaning in the Operated facilities and Director of Care in the contracted facilities.
- 7.3. Contact infection control for additional information during an outbreak.
- 7.4. Discharge cleaning is required upon discontinuation of isolation precautions.

#### 8. Related Fraser Health Policies and Procedures

- 8.1. Fraser Health Residential Care Infection Control Manual:
  - 8.1.1. IC5: 0100 Routine Practices

**Revised December 2013** 



- 8.1.2. Contact precautions
- 8.1.3. Droplet/Contact precautions

### 9. Related Signage

- 9.1. IC6:0410 Appendix I Contact Precautions
- 9.2. IC6:0610 Appendix I Droplet/Contact Precaution

### 10. References

Provincial Infection Control Network (2008). PIC Net Antibiotic Resistant Organism Provincial Guidelines.

http://www.picnetbc.ca//sites/picnetbc2/files/Guidelines/ARO\_Guidelines\_final\_Nov ember2008.pdf

Ministry of Health and Long Term Care (2007). Best Practice for Infection Prevention and Control of Resistant *Staphylococcus Aureus* and *Enterococci*.

http://www.health.gov.on.ca/english/providers/program/infectious/diseases/ic\_staff. html

Adolf W. Karchmer and Arnold S. Bayer. Clinical Methicillin-Resistant *Staphylococcus aureus:* An Evolving Clinical Challenge Infectious Diseases. 2008; 46:S342–3. 2008. [1]

Ari Robicsek, Jennifer L. Beaumont, Suzanne M. Paule, Donna M. Hacek, Richard B. Thomson, Karen L. Kaul, Peggy King, and Lance R. Peterson. Universal Surveillance for Methicillin-Resistant *Staphylococcus aureus* in 3 Affiliated Hospitals. 2008 American College of Physicians [2]

David K. Henderson. Managing methicillin-resistant staphylococci: A paradigm for preventing nosocomial transmission of resistant organisms. doi:10.1016/j.ajic.2006.05.228 [3]

Giuseppe Papia, Marie Louie, Arnold TrallaClaudette Johnson, Veronica Collins, Andrew E. Simor, Screening high-risk patients for methicillin resistant *staphylococcus aureus* on admission to the hospital: is it cost effective? Infection Control and Hospital Epidemiology, July 1999. [4]

John A. Jernigan, Amy L. Pullen, Laura Flowers, Michael Bell, William R. Jarvis. Prevalence Of And Risk Factors For Colonization With Methicillin-Resistant *Staphylococcus Aureus* At The Time Of Hospital Admission. Infection Control And Hospital Epidemiology June 2003. [5]

**Revised December 2013** 

NOTE: This is a controlled document for Fraser Health (FH) internal use only. FH accepts no responsibility for use outside of this health authority. The electronic version of this document Clinical Policy Office is the current version – any printed versions should be checked against the electronic copy.



Katharine L. McGinigle, Margaret L. Gourlay, and Ian B. Buchanan. The Use of Active Surveillance Cultures in Adult Intensive Care Units to Reduce Methicillin-Resistant *Staphylococcus aureus*–Related Morbidity, Mortality, and Costs: A Systematic Review. Clinical Infectious Diseases 2008; 46:1717–25 [6]

Martin E. Stryjewski and Henry F. Chambers. Skin and Soft-Tissue Infections Caused by Community-Acquired Methicillin-Resistant *Staphylococcus aureus*. Clinical Infectious Diseases 2008; 46:S368–77 [7]

Rachel J. Gordon and Franklin D. Lowy. Pathogenesis of Methicillin-Resistant *Staphylococcus aureus* Infection Clinical Infectious Diseases 2008; 46:S350–9

Richard P. Wenzel, MSc; Gonzalo Bearman, Michael B. Edmond. Screening for MRSA: A Flawed Hospital Infection Control Intervention. *Infect Control Hosp Epidemiol* 2008; 29:1012-1018

Robert A. Bonomo.Multiple Antibiotic–Resistant Bacteria in Long-Term-Care Facilities: An Emerging Problem in the Practice of Infectious Diseases. Clinical Infectious Diseases 2000;31:1414–22

Roberto P. Santos, Thomas W. Mayo, and Jane D. Siegel. Active Surveillance Cultures and Contact Precautions for Control of Multidrug-Resistant Organisms: Ethical Considerations. Clinical Infectious Diseases 2008; 47:110–6

Canada Communicable Disease Report, Routine Practices and Additional Precautions for Preventing the Transmission of Infection in Health Care. July 1999, Supplement Volume 25S4

CDC, Management of Multi drug resistant Organisms in Healthcare Settings,2006 Pgs 38, 39 <u>http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf</u>

Giuseppe Papia, Screening High-Risk Patients For Methicillinresistant Staphylococcus Aureus On Admission To The Hospital: Is It Cost Effective?

Stephen G. Weber, Legislative Mandates for Use of Active Surveillance Cultures to Screen for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci: Position Statement From the Joint SHEA and APIC Task Force, 2007

Erin O'Fallen et al.Acquisition of Multidrug-Resistant Gram Negative Bacteria: Incidence and Risk Factors within a long Term Care Population. 2010

**Revised December 2013** 

NOTE: This is a controlled document for Fraser Health (FH) internal use only. FH accepts no responsibility for use outside of this health authority. The electronic version of this document Clinical Policy Office is the current version – any printed versions should be checked against the electronic copy.